LAG3 and lymphoma: In addition, Val-ILs-αCD223, which target T4 regulatory lymphocytes expressing CD223 [58, 59], were also found to effectively alter lymphoma growth in vivo (3-fold decrease, P < 0.01, Fig. 5D).